Wugen has received a major regulatory endorsement from the U.S. Food and Drug Administration, which has granted Breakthrough Therapy Designation to its investigational CAR-T cell therapy, Sofi-cel. The designation is intended to accelerate the development and review of promising treatments for serious or life-threatening conditions and reflects the FDA’s assessment that Sofi-cel may offer substantial clinical improvement for patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Sofi-cel is a potential first-in-class, allogeneic, off-the-shelf CAR-T therapy that targets CD7, a marker commonly expressed in T-cell malignancies. Unlike autologous CAR-T therapies that are manufactured from a patient’s own cells, Sofi-cel is designed for immediate availability, which could be critical for patients with aggressive and rapidly progressing disease. The therapy is currently being evaluated in a pivotal Phase 2 clinical trial known as T-RRex, a single-arm study assessing both safety and efficacy in patients with relapsed or refractory T-ALL/LBL.
The Breakthrough Therapy designation follows a review of data that included results from a global Phase 1/2 clinical trial of Sofi-cel in this patient population. According to the company, the clinical findings to date have demonstrated encouraging activity in a disease setting where treatment options are limited and outcomes are often poor.
This latest designation adds to a growing list of regulatory recognitions for Sofi-cel. The therapy has previously received Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, as well as Priority Medicines designation under the European Union’s PRIME scheme. Together, these designations are designed to facilitate closer interactions with regulators and potentially shorten development and review timelines.
Wugen executives said the Breakthrough Therapy status will allow for more intensive collaboration with the FDA as the company advances Sofi-cel through late-stage development. Company leadership emphasized its commitment to rapidly delivering an off-the-shelf CAR-T option to patients facing relapsed or refractory T-cell leukemias and lymphomas.
The designation underscores the growing momentum behind allogeneic CAR-T approaches and highlights Sofi-cel’s potential to address a critical unmet medical need in hematologic malignancies where therapeutic choices remain limited.